Tirzepatide Once Weekly for the Treatment of Obesity
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. METHODS: In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. RESULTS: At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher. The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo). The percentage of participants who had weight reduction of 5% or more was 85% (95% CI, 82 to 89), 89% (95% CI, 86 to 92), and 91% (95% CI, 88 to 94) with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 35% (95% CI, 30 to 39) with placebo; 50% (95% CI, 46 to 54) and 57% (95% CI, 53 to 61) of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% (95% CI, 1 to 5) in the placebo group (P<0.001 for all comparisons with placebo). Improvements in all prespecified cardiometabolic measures were observed with tirzepatide. The most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation. Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively. CONCLUSIONS: In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many patients treated with GLP-1RAs achieve clinically meaningful weight loss while simultaneously demonstrating improvements in cardiometabolic health.45,46”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [46]
In the citing paper
“with two articles presenting LM outcomes in only a subset of participants from the parent trial (6, 7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Indeed, clinical trials demonstrate substantial weight loss achievable with GLP1Ra-based therapy, ranging from 12-15% over a one-year period for semaglutide (6), to weight losses rivaling what is seen with bariatric surgery for tirzepatide (7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Across body weight and composition outcomes, the greatest magnitude of weight loss was observed in the SURMOUNT (7) and STEP (6) trials, respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“However, the magnitude of the treatment effect on total body mass was nearly two times greater in trials using GLP1Ra-based therapies at dosages indicated primarily for chronic weight management (6, 7, 18, 21, 24) as compared to trials using dosages indicated primarily for diabetes management (17, 19, 20, 22): −10.2 kg (−16.3, −3.9) versus −5.5 kg (−8.7, −2.1), respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
174 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationObesity and cardiovascular disease: a scientific statement from the American Heart Association
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000973 · Cited by 3,691
Di Angelantonio, E., Bhupathiraju, S. N., Wormser, D., Gao, P., Kaptoge, S., de Gonzalez, A. B., Cairns, B. J., Huxley, R., Jackson, C. L., Joshy, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30175-1 · Cited by 2,821
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationObesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506
Self-citationRubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Cited by
Items 2,701–2,800 of 3,704
Dong, J., Starkey, T., Cheng, V. W. T., Clark, J., Pinato, D. J., Robinson, T., Tilby, M., Turnbull, C. D., & Lee, L. Y. W. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4865052
Chronic and Other Conditions That Increase CVD Risk
Arslanian‐Engoren, C., GARY, R. A., Irwin, C., & Zhang, W. (2024) · Springer eBooks · doi:10.1007/978-3-031-53705-9_7 · Cited by 1
Obesity and Atrial Fibrillation: Therapeutic Perspective for GLP-1 Analogs
Szołkiewicz-Płatkowska, A., & Orczykowski, M. (2024) · In a good rythm · doi:10.5604/01.3001.0054.6436 · Cited by 1
Pharmacologic treatment of NAFLD/NASH and their related comorbidities
Kim, S. H., & Kwo, P. Y. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99649-5.00013-3
Advances in detection, prevention and treatment of heart failure in type 2 diabetes: part I
Cowley, A., Dattani, A., Brady, E. M., McCann, G. P., & Gulsin, G. S. (2024) · British Journal of Diabetes · doi:10.15277/bjd.2024.441
Boregowda, K., & Bain, S. C. (2024) · British Journal of Diabetes · doi:10.15277/bjd.2024.443
Prise en charge de l’obésité en 2024
Émile, C. (2024) · Option/Bio · doi:10.1016/s0992-5945(24)74591-7 · Cited by 2
Quevedo, R. D. A. P. (2024) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2024.tde-02072024-161545
Obesity management: A clinician's perspective lečenje gojaznosti iz perspective kliničara
Polovina, S. P., Šumarac-Dumanović, M., & Micić, D. (2024) · Arhiv za farmaciju · doi:10.5937/arhfarm74-50566
Tirzepatide - A Revolution in Obesity Treatment?
Jaroń, A., Jastrzębska, K., Wojciechowska, K., Turek, M., Chaberska, I., Feruś, A., Lipska, J., & Piątkowska, K. (2024) · Quality in Sport · doi:10.12775/qs.2024.17.53102
Chronische Niereninsuffizienz bei Typ-2-Diabetes – die stille Bedrohung einer Multisystemerkrankung
Günes-Altan, M., & Schmieder, R. E. (2024) · Aktuelle Kardiologie · doi:10.1055/a-2318-3452
TIRZEPATIDA - UMA NOVA FARMACOTERAPIA PARA DIABETES MELITTUS TIPO 2
Fontes, L. B. A., & Souza, G. L. D. (2024) · Revista Científica Fagoc. · doi:10.61224/2525-5045.2023.1097 · Cited by 3
Xu, W. J., Schmiesing, C. A., & Chang, J. (2024) · The Journal Of Hand Surgery · doi:10.1016/j.jhsa.2024.05.018
Development of the novel amylin receptor activators with nanomolar potency by peptide mutagenesisPreprint
Lee, S. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.31.606116
Machine learning trims the peptide drug design process to a sweet spot
Markey, C., & Reker, D. (2024) · Nature Chemistry · doi:10.1038/s41557-024-01610-0
Approach to Weight Loss Patient's Post Bariatric Surgery
AlSaeed, A., Algazwi, H., Alsahhaf, M., Alhulail, S., Alsharafaa, A., Alsheef, M. A., Aljowaiher, B., Bomozah, H., Mubarak, A. A., Aldaghdough, H., et al. (2024) · International Journal of Science and Research (IJSR) · doi:10.21275/sr24619141101
Was passiert nach Absetzen der Therapie?
Diener, H. (2024) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-024-3998-4
Sun, R., Ronxhi, J., Yang, X., Qian, M. G., & Zhang, X. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4935710
Don’t These Patients Deserve Better?
Cornu, E., Gaulier, C., Proust, A., & Paepegaey, A. C. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07500-1
14. The Cutting Edge of the Treatment of Type 2 Diabetes
Ogawa, W. (2023) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.112.1740
Abramov, V. V., & Maksimov, M. L. (2024) · Glavvrač (Chief Medical Officer) · doi:10.33920/med-03-2407-03
Ensuring the Appropriate Use of Glucagon‐Like Peptide‐1 Receptor Agonists
Moore, K. T., Gupta, A. S., Shen, J., & Kumar, P. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.6136
Adipositas-Versorgung von Erwachsenen in Deutschland – Aktuelles für die Praxis
Blüher, M., Aberle, J., Clever, S. N., Otto, M., Pfeiffer, A. F. H., Rötzer, R., Schnell, O., & Sandow, P. (2024) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2341-3649 · Cited by 2
Interdisziplinäre Adipositastherapie
Blank, S., & Otto, M. (2024) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2340-0932
Die Schlafqualität wird verbessert
Diener, H. (2024) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-024-4075-8
Tirzepatide: la nuova sfida farmacologica al diabete e all’obesità
Capobianco, E., Pagotto, U., & Garelli, S. (2024) · L Endocrinologo · doi:10.1007/s40619-024-01522-8 · Cited by 1
Response to the Letter to the Editor by Bett et al.
Almandoz, J. P., Wadden, T. A., Tewksbury, C. M., Apovian, C. M., Fitch, A., Ard, J. D., Li, Z., Richards, J. R., Butsch, W. S., Jouravskaya, I., et al. (2024) · Obesity · doi:10.1002/oby.24140
Protocolo terapéutico y seguimiento del paciente con diabetes mellitus tipo 1 y obesidad
Cebada, A. B., Silva, J. B. Q., Escobar-Morreale, H. F., & Chávez, L. N. (2024) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2024.10.006
Protocolo terapéutico de la diabetes mellitus tipo 2 con obesidad y riesgo cardiovascular
Cebada, A. B., Silva, J. B. Q., Escobar-Morreale, H. F., & Chávez, L. N. (2024) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2024.10.014
Farmaci innovativi per il trattamento dell’obesità
Masi, D., Tuccinardi, D., & Watanabe, M. (2024) · L Endocrinologo · doi:10.1007/s40619-024-01535-3 · Cited by 1
Treatment with bariatric surgery in patients with osteogenesis imperfecta and severe obesity
Hald, J. D., Hald, A.-M. W., Harsløf, T., Langdahl, B. L., & Bruun, J. M. (2024) · Bone Reports · doi:10.1016/j.bonr.2024.101811
Updates in pharmacotherapy of obesity
Ogunsakin, A. A., Olakunde, T. I., Fehintola, M. D., Malmberg, I. R., Olakunde, A., & Dokun, A. O. (2024) · Journal of the National Medical Association · doi:10.1016/j.jnma.2024.09.004 · Cited by 1
The glucagon-like peptide-1 (GLP-1) drugs poised to conquer obesity
Yin, J., Liu, Y., & Jia, W. (2024) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2024-0417
Antohi, P. V., Zabara-Antal, A., Stoian, I. A., Pintilie, A.-L., Țău, V., Trofor, A. C., & Crișan-Dabija, R. A. (2023) · Pneumologia · doi:10.2478/pneum-2024-0018
Phillips, C. L., Chapman, J. L., & Yee, B. J. (2024) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2024.102020
Predictors of Resistance Training Behavior among Glucagon-like Peptide 1 Medication Users
Kompf, J. M., & Rhodes, R. E. (2024) · Translational Journal of the American College of Sports Medicine · doi:10.1249/tjx.0000000000000279 · Cited by 1
Two for one: candidate obesity drug boosts energy use and curbs calorie intake
Ardanaz, C. G., & Steculorum, S. M. (2024) · Nature · doi:10.1038/d41586-024-03548-2
당뇨병 치료의 진화: 관해를 향해가는 혁신적 약물치료와 첨단 관리기기의 결합
Choi, J. H., & Moon, M. K. (2024) · Public Health Weekly Report · doi:10.56786/phwr.2024.17.44.4
Risk management of patients with multiple CVDs: what are the best practices?
Harky, A., Patel, R. S. K., Yien, M., Khaled, A., Nguyen, D. H., Roy, S., & Zeinah, M. (2024) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2024.2427634
Impact of a Restrictive Formulary on glycemic control compared with an Open Formulary
Duong, T., Jolliff, J. C., Duvall, A., Aguirre, R., & Lash, D. B. (2024) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.2048
Semaglutide vs Tirzepatide Dosages for Weight Loss—Reply
Rodriguez, P. J., Gluckman, T. J., & Stucky, N. L. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.5771
V CardioMIR: el Congreso de los Jóvenes Cardiólogos
Monterde, E. M., Rodríguez, A. J. W., Duran, Ö., & Laffond, A. E. (2024) · REC CardioClinics · doi:10.1016/j.rccl.2024.10.008
Prescrizione dietetica nell’ipertensione arteriosa
Vay‐Demouy, J., Fenech, G., Kantor, B., Cinaud, A., & Blacher, J. (2024) · EMC - AKOS - Trattato di Medicina · doi:10.1016/s1634-7358(24)49632-0 · Cited by 1
Super response to liraglutide in people with obesity: A case report and literature review
Medina, S. G., Campayo, E. S., Guadalix, S., & Escalada, J. (2024) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2024.11.012 · Cited by 1
Les différentes approches thérapeutiques de l’obésité : comparaison en termes d’efficience
Monnier, L., Halimi, S., & Colette, C. (2024) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.11.007 · Cited by 1
Prise en charge pharmacologique de l’obésité : l’apport des nouvelles classes médicamenteuses
Bauduceau, B., Bordier, L., Schlienger, J.-L., & Monnier, L. (2024) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.11.008 · Cited by 5
Approche thérapeutique de l’obésité via la restriction calorique traditionnelle
Monnier, L., Colette, C., Azrak, A. E., Essekkat, N., Bakri, A., & Rochd, D. (2024) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.11.006
Was passiert nach Absetzen von Tirzepatid?
Diener, H. (2024) · Info Diabetologie · doi:10.1007/s15034-024-5044-5
Anhaltende Gewichtseffekte mit Inkretin-basierten Therapien
Willen, C. (2024) · Info Diabetologie · doi:10.1007/s15034-024-5051-6
Adipose Tissue Dysfunction: Clinical Implications and Complications
Dronkers, J., Lobeek, M., Meems, L. M. G., & Gorter, T. M. (2024) · Contemporary Endocrinology · doi:10.1007/978-3-031-72570-8_5
Einfluss der Adipositas in der Urogynäkologie
Stark, S., Aktas, B., & Kempe, T. (2024) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2413-9339
Grave, R. D., Sartirana, M., & Calugi, S. (2024) · Springer eBooks · doi:10.1007/978-3-031-71456-6_12
Mutchmore, A., Cauchon, M., Plourde, M.-É., & Lanthier, L. (2024) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2024.12.002
Pharmacological Interventions of Metabolic Syndrome
Mehta, A. A., Beladiya, J., & Gandhi, T. (2024) · Advances in biochemistry in health and disease · doi:10.1007/978-3-031-75686-3_22 · Cited by 2
Auerbach, N., Liu, V. N., Huang, D. R., Clift, A. K., Al-Ammouri, M., & El-Osta, A. A. R. (2024) · Research Square · doi:10.21203/rs.3.rs-5689779/v1
Medically Supervised Weight Loss and Effects of Anti-Obesity Medications
Sheer, A. J., Donahoo, W. T., & Johnson-Mann, C. N. (2024) · Springer eBooks · doi:10.1007/978-3-031-72309-4_14
Metabolic Steatohepatitis After Liver Transplantation
Ferrarese, A., Battistella, S., Russo, F. P., & Burra, P. (2024) · Springer eBooks · doi:10.1007/978-981-97-9519-2_14
Liver Steatosis: From Lipotoxicity to Cellular Damage
Puengel, T., & Tacke, F. (2024) · Springer eBooks · doi:10.1007/978-981-97-9519-2_4 · Cited by 3
Metabolic syndrome in the post-ETI era
Litvin, M. (2024) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2024.12.008
Challenges and Novelties in the Treatment of Obesity in Adults. A review
Kuczapska, K., Kurowski, M., Gliwa, A., Ryglewicz, M., Fabian, D., Leszczyńska-Knaga, E., Jakubczyk, N., Rutkowska-Kawalec, W., Moczydłowski, P., & Michalczuk, K. (2025) · Journal of Education Health and Sport · doi:10.12775/jehs.2025.77.57095
Thérapeutiques de l’obésité et maladies cardiovasculaires
Lassen, P. B., & Aron‐Wisnewsky, J. (2025) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/j.amcp.2024.12.006
Li, J., Ni, W., Bai, X., Zhou, S., Wu, X., Li, J., Jiang, Z., Wu, J., Li, M., Wong, H.-N., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5083838
Would a weekly shot be enough to solve the obesity problem? a new denial of a complex reality
Duparc, A., Terral, P., & Lairez, O. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf002
Refractory Dysmenorrhea Managed With a Glucagon-Like Peptide-1 Agonist: A Case Report
Tran, M., Swartz, N., & Elisèe, S. D. (2025) · Cureus · doi:10.7759/cureus.77387
The Impact of Obesity Treatments on Bone Health: Insights from Recent Research
Heo, J. H. (2025) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes25001 · Cited by 1
Liuzzo, G., & Patrono, C. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf013
Lange, M. G., & Kalidindi, S. (2025) · Obesity Surgery · doi:10.1007/s11695-025-07704-z
Real-life data about obesity management
Deviere, J. M. E. (2025) · Endoscopy International Open · doi:10.1055/a-2515-1487
SUMMIT: Tirzepatide reduces cardiovascular events in HFpEF plus obesity
van den Heuvel, R. (2025) · doi:10.55788/d9fd7622
Halimi, S. (2025) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2025.01.012
Medical management of obesity: unlocking the potential
Xiang, A. S., & Sumithran, P. (2025) · Climacteric · doi:10.1080/13697137.2025.2455177 · Cited by 1
Nouvelles approches pharmacothérapeutiques pour la gestion de l’obésité
Sollier, C., & Jacobi, D. (2025) · Pratiques en nutrition · doi:10.1016/j.pranut.2025.01.009
Greener, M. (2025) · Independent Nurse · doi:10.12968/indn.2025.2.8
Browning, T. E., Coy, A., Sehgal, V., Singh, S., Jakhar, N. S., Sehgal, P., & Kukreja, M. (2025) · doi:10.25259/peak_19_2024 · Cited by 1
Karnosová, P. (2025) · Medicína pro praxi · doi:10.36290/med.2025.003
Lessing, Y., Dvir, N., Kanani, F., Eldar, S. M., Keidar, A., Lahat, G., & Abu-Abeid, A. (2025) · Bariatric Surgical Practice and Patient Care · doi:10.1089/bari.2024.0038
Promising treatment options with tirzepatide for Japanese individuals with obesity disease
Nauck, M. A., & Lim, S. K. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00024-5
Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?
Stüdemann, S., & Engeli, S. (2025) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2492-9440
Marmett, B., da Silva, I., Lira, F. S., & Dorneles, G. P. (2025) · Translational Exercise Biomedicine · doi:10.1515/teb-2024-0039 · Cited by 6
Role of Incretin Mimetics in the Management of Obesity
Garcha, S. C., & Kalra, S. (2025) · Springer eBooks · doi:10.1007/978-981-96-1651-0_4 · Cited by 1
Johnson, J., Benzer, J. A., Salvati, L. A., Westerhof, L., & Lepoire, A. (2025) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.70024 · Cited by 2
Anti-Obesity Agents on the Horizon
Kim, S. H. (2025) · Korean Journal of Family Practice · doi:10.21215/kjfp.2025.15.1.2
Tirzepatide as an Emerging Modality for Management of Obstructive Sleep Apnea
Gothi, D., Ish, P., & Malhotra, N. (2025) · Indian Journal of Sleep Medicine · doi:10.5005/jp-journals-10069-0151
CRISPR-Cas9 Screening Reveals Microproteins Regulating Adipocyte Proliferation and Lipid MetabolismPreprint
Pai, V. J., Shan, H., Donaldson, C. J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.21.644636
Oliveira, C. W. D. M., da Silva, J. C. P., Viana, V. C. D. A., Caracas, M. M. T., Machado, J. P. A., Oliveira, D. F., Benicio, L. A. D. O., Santos, A. D. S., Guimarães, N. M. X. P., Cahú, M. L. V., et al. (2025) · Revista Contemporânea · doi:10.56083/rcv5n3-093
Injectable Drugs in Diabetes Treatment: Insulin versus Incretin
Ahn, K. H. (2025) · Journal of Korean Diabetes · doi:10.4093/jkd.2025.26.1.28
Rampy, J., Torres-Manzo, A. P., Hoffsmith, K., Loberg, M. A., Sheng, Q., Salas-Lucia, F., Bianco, A. C., Drigo, R. A. E., Wang, H., Weiss, V. L., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.31.645596
Hypertension in People with Diabetic and Chronic Kidney Disease, Obesity, and Renin Secreting Tumors
Khan, S. H., & Weir, M. R. (2025) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-81292-7_3 · Cited by 2
Metabolische unerwünschte Arzneimittelwirkungen von Psychopharmaka
Gahr, M. (2025) · Diabetes aktuell · doi:10.1055/a-2539-1129
Therapieprinzipien bei Adipositas – was ändert sich in der aktualisierten S3-Leitlinie?
Rohmann, N., Hollstein, T., & Laudes, M. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-01900-w · Cited by 1
Tirzepatide in the NHS : The known unknowns of treating obesity at a national scale
Clift, A. K., Auerbach, N., Liu, V. N., Johnson, H. H., Curtis, T., & Huang, D. R. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16375
OBE-DB: A Computational Tool and Web Server for the Prediction of Antiobesity DrugsPreprint
García, E. M., Martínez-Cortés, C., Banegas‐Luna, A. J., Morante, J. J. H., & Pérez‐Sánchez, H. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.10.648110
McGuigan, A. (2025) · Drugs & Therapy Perspectives · doi:10.1007/s40267-025-01154-4
Bariatric surgery and infertility treatment: unveiling insights for modern pharmacotherapy
Manuel, E., & Schon, S. B. (2025) · F&S Reports · doi:10.1016/j.xfre.2025.04.002
Pedicino, D., & Liuzzo, G. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf236
Lassen, P. B. (2025) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2024.12.015
Identification of a Thermogenic Target in the Dorsal Raphe Nucleus for Weight ManagementPreprint
Moura‐Assis, A., Plucińska, K., Baleisyte, A., Meseguer, D., Chen, B., Pellegrino, K., Parolari, L., Shaked, J. T., Page, K. J., Barrows, D. W., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.24.650283
Nouveaux médicaments de l’obésité : quelle pertinence ?
Bringer, J. (2025) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2025.02.008
Harrigfeld, S., & Elmes, A. T. (2025) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.70047
The Patient Evaluation and Optimization of Modifiable Risk Factors Before Revision THA
Novikov, D., Bartashevskyy, M., & Abdeen, A. R. (2025) · Springer eBooks · doi:10.1007/978-3-031-83959-7_13 · Cited by 1
Metadata
- Authors
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A.
- Affiliations
- Eli Lilly (United States) (US)
- From the Section of Endocrinology and Metabolism, Department of Medicine, and the Section of Pediatric Endocrinology, Department of Pediatrics, Yale University School of Medicine, New Haven, CT (A.M.J.); the Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York (L.J.A.); Eli Lilly, Indianapolis (N.N.A., S.Z., B.L., M.C.B., A.S.); McMaster University, Hamilton, and York University and Wharton Weight Management Clinic, Toronto — all in Ontario, Canada (S.W.); Intend Research, Norman, OK (L.C.); Centro Paulista De Investigação Clínica (Cepic), Sao Paulo (B.A.); and Tokyo-Eki Center-Building Clinic, Tokyo (A.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-21
- Volume
- 387
- Issue
- 3
- Pages
- 205-216
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4281934192
- Semantic Scholar
- 3fb03384cc726ebd9d08c76482e6edf35502d0c7
- Cited by
- 3,838
- References
- 28
- Citations by year
- 2026: 1279 · 2025: 1067 · 2024: 776 · 2023: 562 · 2022: 149
- FWCI
- 382.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- tirzepatide, obesity, weight loss, GLP-1 receptor agonists, GIP receptor agonist, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, dose escalation, body mass index, weight-related comorbidities, treatment discontinuation, treatment-emergent adverse events, drug safety, subcutaneous administration
- MeSH terms
- Tirzepatide, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Glucagon-Like Peptides, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Obesity, Weight Loss, Treatment Outcome, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.